Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Blood

Volumn 129, Issue 18, 2017, Pages 2519-2525

  Xu, Lian ^a   Tsakmaklis, Nicholas ^a   Yang, Guang ^a,b   Chen, Jiaji G ^a   Liu, Xia ^a   Demos, Maria ^a   Kofides, Amanda ^a   Patterson, Christopher J ^a   Meid, Kirsten ^a   Gustine, Joshua ^a   Dubeau, Toni ^a   Palomba, M Lia ^c   Advani, Ranjana ^d   Castillo, Jorge J ^a,b   Furman, Richard R ^e   Hunter, Zachary R ^a,b   Treon, Steven P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BRUTON TYROSINE KINASE; CASPASE RECRUITMENT DOMAIN PROTEIN 11; CD19 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CXCR4; HEMATOPOIETIC CELL KINASE; IBRUTINIB; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE LYN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MALE; MIDDLE AGED; MOLECULAR CLONING; NESTED ALLELE SPECIFIC POLYMERASE CHAIN REACTION; NEXT GENERATION SEQUENCING; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SANGER SEQUENCING; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SOMATIC MUTATION; VERY ELDERLY; WALDENSTROEM MACROGLOBULINEMIA; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; WALDENSTROM MACROGLOBULINEMIA;

AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; WALDENSTROM MACROGLOBULINEMIA;

EID: 85019107939     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-01-761726     Document Type: Article

References (28)

1. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367(9):826-833.
2. Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. Leukemia. 2013;27(8):1722-1728.
3. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522-2528.
4. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637-1646.
5. Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood. 2014;123(18):2791-2796.
6. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123(26):4120-4131.
7. Cao Y, Hunter ZR, Liu X, et al. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenström's macroglobulinemia. Leukemia. 2015;29(1):169-176.
8. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372(15):1430-1440.
9. Palomba ML, Bantilan K, Meid K, et al. Long-term follow-up of a pivotal phase II trial of ibrutinib for relapsed Waldenström's macroglobulinemia. In: Proceedings from the 9th International Workshop on Waldenström's macroglobulinemia; 5 October-8 October 2016; Amsterdam, The Netherlands. Available at: www.wmworkshop.org.
10. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström's macroglobulinemia. N Engl J Med. 2015;373(6):584-586.
11. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18(2):241-250.
12. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.
13. Furman RR, Cheng S, Lu P, et al. Ibrutinib resistance in chronic lymphocytic leukemia [published correction appears in N Engl J Med. 2014;370(26):2547]. N Engl J Med. 2014;370(24):2352-2354.
14. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
15. Sharma S, Galanina N, Guo A, et al. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. Oncotarget. 2016;7(42):68833-68841.
16. Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016;7:11589. doi:10.1038/ncomms11589.
17. Chiron D, Di Liberto M, Martin P, et al. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2014;4(9):1022-1035.
18. Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction [published correction appears in Blood. 2013;121(26):5259]. Blood. 2013;121(11):2051-2058.
19. Xu L, Hunter ZR, Yang G, et al. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014;28(8):1698-1704.
20. Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia. Br J Haematol. 2016;172(5):735-744.
21. SureCall. Available at: http://www.agilent.com/ search/?Ntt=surecall. Accessed 10 January 2017.
22. ExAC Browser (Beta). Exome Aggregation Consortium. Available at: http://exac.broadinstitute.org. Accessed 10 January 2017.
23. Hunter ZR, Xu L, Yang G, et al. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016;128(6):827-838.
24. Hamasy A, Wang Q, Blomberg KE, et al. Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. Leukemia. 2017;31(1):177-185.
25. 2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. Blood. 2015;126(1):61-68.
26. Wu C, de Miranda NF, Chen L, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180-38190.
27. Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21(8):922-926.
28. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013;122(7):1222-1232.